Browse by author
Lookup NU author(s): Dr Chris RedfernORCiD,
Professor Penny Lovat,
Professor Archibald Malcolm,
Professor Andrew Pearson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Retinoic acid has considerable potential for the chemoprevention and chemotherapy of cancer. Neuroblastoma cells differentiate in response to retinoic acid in vitro, an observation that has led to clinical trials using either the 13-cis or all-trans isomers of retinoic acid. We review the effects of retinoic acid on neuroblastoma, and the potential involvement of nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs). 9-cis retinoic acid is a ligand for RXRs, and we review recent data on the differential effects of 9-cis and all-trans retinoic acid on neuroblastoma differentiation and proliferation in vitro, and possible mechanisms of action via hetero- and homodimers of RARs and RXRs. Although there is uncertainty whether or not 9-cis retinoic acid produces its biological effects primarily via RXR homodimers, in vitro data suggest that this isomer of retinoic acid or stable analogues may have considerable potential for the treatment of resistant, disseminated neuroblastoma.
Author(s): Redfern CPF, Lovat PE, Malcolm AJ, Pearson ADJ
Publication type: Article
Publication status: Published
Journal: European Journal of Cancer
Print publication date: 01/01/1995
ISSN (print): 0959-8049
ISSN (electronic): 1879-0852
PubMed id: 7576951
Altmetrics provided by Altmetric